Vertex EVP Atkinson awarded 7,817 VRTX shares

Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported the vesting of performance-based stock awards.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported the vesting of performance-based stock awards. On January 22, 2026, he acquired 3,934 shares of Vertex common stock tied to a performance stock unit grant from February 1, 2023, and 3,883 shares tied to a performance stock unit grant from February 12, 2025, both at a price of $0 per share as earned performance shares.

The compensation committee certified achievement of the performance goals on January 22, 2026. The shares from the 2023 grant are scheduled to vest on February 13, 2026, while the 2025 grant will vest in installments beginning on February 24, 2026. Following these transactions, Atkinson directly holds 24,669 shares of Vertex common stock.

Insider Trade Summary

Grant/Award: 7,817 shares

Grant/Award 2 txns

Insider Atkinson Edward Morrow III

Role EVP, Chief Technical Ops. Off.

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,934	$0.00	$0.00
Grant/Award	Common Stock	3,883	$0.00	$0.00

Holdings After Transaction: Common Stock — 24,669 shares (Direct)

Footnotes (2)

1. F1. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.
2. F2. Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the insider in this Vertex (VRTX) Form 4 filing?

The insider is Edward Morrow Atkinson III, who serves as EVP, Chief Technical Operations Officer at Vertex Pharmaceuticals.

How many Vertex (VRTX) shares did Edward Atkinson acquire in this Form 4?

Edward Atkinson acquired 3,934 shares of common stock from a 2023 performance award and 3,883 shares from a 2025 performance award, for a total of 7,817 shares reported as acquired at $0 per share.

What type of compensation do the reported Vertex (VRTX) shares represent?

The reported shares represent earned performance shares from performance stock unit awards that vested based on achievement of specified performance goals certified by the compensation committee.

When will the newly earned Vertex (VRTX) performance shares vest?

Shares from the February 1, 2023 grant are scheduled to vest on February 13, 2026, and shares from the February 12, 2025 grant will vest in installments beginning on February 24, 2026.

How many Vertex (VRTX) shares does Edward Atkinson own after these transactions?

After the reported transactions, Edward Atkinson directly beneficially owns 24,669 shares of Vertex common stock.

Were these Vertex (VRTX) shares bought on the open market?

No. The Form 4 shows the transaction code "A" and a $0 per share price, indicating the shares were acquired through equity compensation, not open-market purchases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/26/2026 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Atkinson Edward Morrow III

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Technical Ops. Off.

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		A		3,934(1)	A	$0	20,786	D
Common Stock	01/22/2026		A		3,883(2)	A	$0	24,669	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

2. Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.